HealthPolitics

STAT+: Ultragenyx cuts staff after another study fails

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/11/2026, 01:52:24 UTC.

Briefings

Novo Nordisk announced the departure of CFO Karsten Munk Knudsen and the hiring of Luigi La Corte following a failed study, while simultaneously securing a $358 million licensing deal with China's Sino Biopharmaceutical Limited for six pre-clinical cancer drugs. The article notes that Democratic control of Congress may pressure drug prices, but the specific impact on Novo Nordisk's strategy remains unconfirmed.

Key points

• Novo Nordisk replaced CFO Karsten Munk Knudsen with Luigi La Corte after a study failed.
• Novo Nordisk signed a $358 million licensing deal with China's Sino Biopharmaceutical Limited for six pre-clinical cancer drugs.

Context

Novo Nordisk's financial leadership changed following a study failure, while a major new partnership with China's Sino Biopharmaceutical Limited secured $358 million upfront payments for pre-clinical cancer drugs, potentially influencing future drug pricing dynamics under Democratic control.

Limitations

The article does not specify the study that failed, nor does it confirm the exact impact of the new China partnership on Novo Nordisk's strategy or drug pricing beyond general policy pressure.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/11/2026, 10:37:49 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeigprbmijs6hvpf7n3463ofnmukogai4lgtdogma657rxwgrmc5zs4